SAB Biotherapeutics, Inc.

SABS

SAB Biotherapeutics, Inc.

SABS

Insider Sentiment (TTM):

Last Purchase:2023-12-07Last Sale:2021-10-26Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:69,134,934Shares Outstanding:53,558,639Institutional Ownership Pct.:129.08%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	8	21	11	29	4	6	9	9	17	14	57	2
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	0	0
Short Term Investments	94	87	86	81	2	7	12	21	20	30	0	-
Accrued Investment Income Receivable	2	2	1	1	0	0	0	0	0	0	0	-
Prepaid Expense And Other Assets Current	3	4	4	2	4	3	3	2	2	3	2	1
Assets Current	108	113	101	113	9	16	24	33	40	47	59	3
Deferred Finance Costs Net	-	0	0	0	0	0	0	0	0	0	0	-
Long Term Investments	105	110	47	51	-	-	-	-	-	1	-	-
Operating Lease Right Of Use Asset	2	3	3	3	3	3	1	1	1	1	1	0
Finance Lease Right Of Use Asset	-	3	3	4	4	4	4	4	4	4	4	4
Property Plant And Equipment Net	14	14	13	13	14	15	15	16	17	18	20	21
Assets	238	248	173	183	30	38	44	54	62	71	84	28
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	4	3	3	3	3	2	1	1	1	1	1
Notes Payable Current	-	-	0	0	0	0	0	0	1	1	1	1
Accounts Payable And Other Accrued Liabilities Cur…	7	5	7	7	7	6	5	7	5	5	7	5
Deferred Income Current	-	-	-	-	-	-	0	0	0	0	1	2
Operating Lease Liability Current	0	1	1	1	1	1	0	0	0	1	1	1
Finance Lease Liability Current	-	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	12	10	11	11	11	10	8	9	8	8	11	9
Operating Lease Liability Noncurrent	1	2	2	2	2	2	1	1	1	1	1	0
Finance Lease Liability Noncurrent	-	3	3	3	3	3	3	3	3	3	3	3
Long Term Notes Payable	-	-	-	-	-	-	-	-	-	-	0	-
Derivative Liabilities Noncurrent	7	6	6	2	2	1	6	4	4	6	12	0
Liabilities	23	21	21	18	18	17	18	17	16	19	27	13
Stockholders Equity
Preferred Stock Value	-	-	-	-	0	0	0	0	0	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Value	-6	-6	-6	-6	-6	-6	-6	-6	-6	-6	-6	-6
Additional Paid In Capital	373	363	268	265	157	156	156	155	154	153	153	88
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	-0	-0	-0	0	-0	-0	0	-
Retained Earnings Accumulated Deficit	-152	-130	-111	-94	-139	-129	-124	-113	-102	-95	-90	-67
Stockholders Equity	215	227	151	165	12	21	26	37	46	53	57	15
Liabilities And Stockholders Equity	238	248	173	183	30	38	44	54	62	71	84	28
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	-	-	-	-	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	-	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	800	800	800	800	800	800	800	800	800	800	800	490
Common Stock Shares Issued	84	76	48	48	9	9	9	9	9	9	9	5
Shares Outstanding	83	76	48	47	9	9	9	9	9	9	9	5
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	1
Stockholders Equity Note Stock Split Conversion Ra…	-	-	-	-	-	-	-	-	-	-	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.63%	8.29%	-1.38%	-	-	-	-	-	-	-	-	-
2025	7.82%	-5.59%	42.46%	-6.73%	-9.87%	35.87%	22.84%	16.36%	35.49%	1.04%	-9.64%	-6.25%
2024	-8.70%	-13.33%	-31.59%	8.49%	-5.17%	2.21%	-26.08%	5.82%	3.80%	28.68%	33.09%	31.62%
2023	-	-	-	-17.72%	-11.14%	22.78%	-9.57%	-37.42%	-35.91%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.22	11.45	9.46	10.50	0.87	1.69	2.98	3.69	5.24	5.65	5.45	0.34
Quick Ratio	8.93	11.06	9.13	10.32	0.54	1.33	2.61	3.46	4.97	5.33	5.23	0.26
Working Capital	96.23M	102.93M	90.37M	102.48M	-1.37M	6.64M	15.81M	23.72M	32.03M	38.65M	48.09M	-6.08M
Leverage & Debt
Debt to Equity	0.11	0.09	0.14	0.11	1.51	0.78	0.70	0.46	0.34	0.35	0.46	0.86
Interest Coverage TTM	-309.79	-248.79	-203.41	-174.35	-148.06	-135.73	-134.77	-159.11	-144.41	-140.56	-120.77	-83.24
Debt Ratio	0.10	0.09	0.12	0.10	0.60	0.44	0.41	0.31	0.25	0.26	0.32	0.46
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.03	0.03	0.04	0.08	0.07	0.06	0.04	0.10
Per Share Metrics
Diluted EPS TTM	-0.16	-0.01	0.22	0.24	-3.99	-3.69	-3.68	-4.92	-4.36	-4.31	-7.64	-5.19
Free Cash Flow Per Share TTM	-0.62	-0.98	-2.32	-2.79	-2.49	-3.40	-3.74	-4.16	-4.04	-3.74	-4.59	-2.57
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	109.20%	109.15%	110.85%	107.94%
Operating Profit Margin TTM	-	-	-	-37,657.07%	-3,162.58%	-2,667.34%	-1,695.99%	-1,528.63%	-1,328.49%	-1,286.72%	-1,310.41%	-660.87%
Net Profit Margin TTM	-	-	-	16,338.56%	-2,802.07%	-2,161.80%	-1,347.97%	-1,345.34%	-1,169.82%	-1,219.48%	-1,452.15%	-664.53%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-100.00%	-96.61%	-61.63%	-51.50%	-12.92%	-17.29%	-46.29%	-74.22%	-87.84%	-87.52%
Net Income Growth (1Y)	-65.52%	-98.84%	-138.92%	-141.13%	-8.10%	-14.02%	-19.17%	67.46%	38.15%	47.21%	125.14%	21.38%
EPS Growth (1Y)	-95.98%	-99.80%	-118.67%	-135.72%	-8.49%	-14.48%	-51.81%	-5.22%	-24.73%	-19.72%	77.48%	-0.33%
Valuation Metrics
P/E TTM	-24.35	-514.85	5.44	1.14	-0.44	-0.37	-1.03	-0.55	-0.71	-1.05	-0.90	-1.21
P/B TTM	1.45	0.90	0.48	0.13	1.36	0.59	1.35	0.68	0.62	0.79	0.66	2.16
P/S TTM	-	-	-	186.82	12.33	7.97	13.89	7.38	8.32	12.83	13.07	8.06
Market Cap	311.04M	205.13M	72.23M	21.43M	16.31M	12.64M	35.14M	25.00M	28.69M	41.96M	37.99M	33.02M
Enterprise Value	302.77M	187.85M	65.00M	-4.68M	15.97M	10.52M	29.94M	19.28M	15.55M	32.28M	-13.98M	34.71M
Calculated Values
Free Cash Flow TTM	-49.05M	-52.23M	-44.78M	-29.79M	-23.13M	-31.55M	-34.63M	-38.56M	-37.42M	-34.57M	-25.32M	-13.47M
Net Debt	-8.27M	-17.28M	-7.23M	-26.11M	-343.65K	-2.12M	-5.20M	-5.72M	-13.14M	-9.68M	-51.96M	1.70M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-12-07Purchase

Owner: Sullivan, Eddie Joe

Title: Chief Executive Officer

Shares: 1,740

Price/Share: $0.88

Value: $1,531.20

Shares Owned: 5,232,304

Relationship: Director,Officer

Ownership: Direct

2023-11-30Purchase

Owner: King, Michael

Title: CHIEF FINANCIAL OFFICER

Shares: 5,000

Price/Share: $0.90

Value: $4,500.00

Shares Owned: 5,000

Relationship: Officer

Ownership: Direct

2023-11-29Purchase

Owner: Reich, Samuel J

Title: Executive Chairman

Shares: 11,000

Price/Share: $0.89

Value: $9,790.00

Shares Owned: 219,001

Relationship: Director,Officer

Ownership: Direct

2022-09-13Purchase

Owner: Hamilton, Christine E

Title: -

Shares: 10,000

Price/Share: $0.73

Value: $7,300.00

Shares Owned: 4,993,090

Relationship: Director,TenPercentOwner

Ownership: Direct

2022-09-07Purchase

Owner: Sullivan, Eddie Joe

Title: CHIEF EXECUTIVE OFFICER

Shares: 14,000

Price/Share: $0.74

Value: $10,360.00

Shares Owned: 5,230,564

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-12-07	Sullivan, Eddie Joe	Director,Officer	Chief Executive Officer	Direct	Purchase	1,740	0.88	$1,531.20	5,232,304	4
2023-11-30	King, Michael	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	5,000	0.90	$4,500.00	5,000	4
2023-11-29	Reich, Samuel J	Director,Officer	Executive Chairman	Direct	Purchase	11,000	0.89	$9,790.00	219,001	4
2022-09-13	Hamilton, Christine E	Director,TenPercentOwner	-	Direct	Purchase	10,000	0.73	$7,300.00	4,993,090	4
2022-09-07	Sullivan, Eddie Joe	Director,Officer,TenPercentOwner	CHIEF EXECUTIVE OFFICER	Direct	Purchase	14,000	0.74	$10,360.00	5,230,564	4
2021-10-26	Beyer, Russell P	Officer	Chief Financial Officer	Indirect	Sale	278	7.90	$2,196.20	0	4
2021-10-14	Reich, Samuel J	Director,Officer,TenPercentOwner	CEO and CFO	Direct	Purchase	1,000	10.11	$10,110.00	1,000	4
2021-10-13	Katz, Ilan	Director,TenPercentOwner	-	Direct	Purchase	500	10.11	$5,055.00	1,500	4
2021-10-01	Spragens, Jeffrey G	Director	-	Direct	Purchase	13,000	10.07	$130,910.00	13,000	4
2021-10-01	Katz, Ilan	Director,TenPercentOwner	-	Direct	Purchase	1,000	10.09	$10,090.00	1,000	4
2021-01-14	Katz, Ilan	Director,TenPercentOwner	-	Indirect	Purchase	417,200	10.00	$4,172,000.00	3,047,825	4
2021-01-14	Big, Cypress Holdings Llc	Director,Officer,TenPercentOwner	CEO and CFO	Direct	Purchase	417,200	10.00	$4,172,000.00	3,047,825	4
2021-01-14	Reich, Samuel J	Director,Officer,TenPercentOwner	CEO and CFO	Indirect	Purchase	417,200	10.00	$4,172,000.00	3,047,825	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

129.08%

Inst. Shares: 69,134,934

Shares Outstanding: 53,558,639

2025-12-31

188.09%

Inst. Shares: 36,323,144

Shares Outstanding: 19,311,798

2025-09-30

262.51%

Inst. Shares: 27,985,009

Shares Outstanding: 10,660,500

2025-06-30

20.49%

Inst. Shares: 1,904,817

Shares Outstanding: 9,294,469

2025-03-31

23.58%

Inst. Shares: 2,190,585

Shares Outstanding: 9,291,641

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	69,134,934	53,558,639	129.08%
2025-12-31	36,323,144	19,311,798	188.09%
2025-09-30	27,985,009	10,660,500	262.51%
2025-06-30	1,904,817	9,294,469	20.49%
2025-03-31	2,190,585	9,291,641	23.58%
2024-12-31	2,609,285	9,261,918	28.17%
2024-09-30	3,122,369	9,259,192	33.72%
2024-06-30	3,107,784	9,255,025	33.58%
2024-03-31	3,339,616	9,241,940	36.14%
2023-12-31	25,863,887	5,521,487	-
2023-09-30	2,905,750	5,240,600	55.45%
2023-06-30	2,967,126	5,042,126	58.85%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

SAB Biotherapeutics, Inc. (SABS) — SEC Financial Statements & Analysis

SAB Biotherapeutics, Inc. (SABS) is a biological products, (no diagnostic substances) company, incorporated in DE. SAB Biotherapeutics, Inc. trades on Nasdaq as: SABS, SABSW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), SAB Biotherapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Gross Profit Margin of 109.20% (TTM), a Debt-to-Equity ratio of 0.11x, a Price-to-Sales (P/S) ratio of 186.82x (TTM), a Price-to-Book (P/B) ratio of 1.45x (TTM), at a market cap of $311.04M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Gross Profit Margin TTM: 109.20%
Debt To Equity: 0.11x
P/S TTM: 186.82x
P/B TTM: 1.45x
Market Cap: $311.04M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is SAB Biotherapeutics, Inc. in?

SAB Biotherapeutics, Inc. (SABS) operates in the Biological Products, (No Diagnostic Substances) industry.

What is SABS's market cap?

SAB Biotherapeutics, Inc. (SABS) has a market capitalization of $311.04M as of 2026-06-30.

What exchange does SABS trade on?

SAB Biotherapeutics, Inc. (SABS) trades on the Nasdaq.

Where is SAB Biotherapeutics, Inc. incorporated?

SAB Biotherapeutics, Inc. is incorporated in DE.